1. Infarmed – Autoridade Nacional do Medicamento e Produtos de Saúde, I. P. Deliberacão No. 11/CD/2019. January 31, 2019.
2. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessed September 1, 2021: https://clinicaltrials.gov/ct2/results?cond=&term=Cannabis&cntry=&state=&city=&dist=
3. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015 Oct;12(4): 692-8.
4. Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. 2017 Sep; 124: 105-20.
5. Health Canada. Information for Health Care Professionals: Cannabis and the cannabinoids. October 2018. ISBN: 978-0-660-27828-5.
6. Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018 Oct;22(9): 1547-64.
7. Mesquita G, Pedro A, Fonseca B, Fonseca R. Recomendações da Associação Portuguesa para o Estudo da Dor (APED) para a utilização de canabinoides na dor crónica. APED. December 2020.
8. Centonze D. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. Eur Neurol. 2014;72 Suppl 1:6-8.
9. Solari A, Giordano A, Sastre-Garriga J, et al. EAN guideline on palliative care of people with severe, progressive multiple sclerosis. Eur J Neurol. 2020 Aug;27(8): 1510-29.
10. Sociedade Portuguesa de Neurologia [website]. Accessed December 20, 2021: https://www.spneurologia.com/
11. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):287-302.
12. Infarmed. Informação aos profissionais de saúde sobre produtos à base de canábis medicinal. Tilray Flor Seca THC18. Aprovado em 27.01.2021.
13. Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients. Aachen, Department of Palliative Medicine: European Palliative Care Research Collaborative; 2010.
14. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1): 11-48.
15. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004 Jul-Aug;2(4): 305-14; discussion 314-6.
16. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23-30;313(24): 2456-73. Erratum in: JAMA. 2015 Aug 4;314(5):520. Erratum in: JAMA. 2015 Aug 25;314(8): 837. Erratum in: JAMA. 2015 Dec 1;314(21): 2308. Erratum in: JAMA. 2016 Apr 12;315(14): 1522. PMID: 26103030.
17. Bar-Sela G, Vorobeichik M, Drawsheh S, Omer A, Goldberg V, Muller E. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evid Based Complement Alternat Med. 2013 Jul;2013:510392.
18. Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005 Aug;181(1): 170-8.
19. Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007 Aug;45(5): 545-54.
20. Associação Portuguesa de Cuidados Paliativos: Webcast Wecare – Utilização da Cannabis medicinal em contexto de Cuidados Paliativos [website]. July 14, 2021. Accessed December 20, 2021: https://apcp.com.pt/157557/webcast-wecare-utilizacao-da-cannabis-medicinal-em-contexto-de-cuidados-paliativos
21. Sociedade Portuguesa de Oncologia. https://www.sponcologia.pt/pt/
22. Berger MJ, Ettinger DS, Aston J, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 Jul;15(7): 883-93.
23. Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017 Dec;7(2):61-76.
24. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015 Oct;12(4): 747-68.
25. Epidyolex® Summary of Product Characteristics. GW Pharma. July 2021.
26. McCoy B, Wang L, Zak M, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl. Neurol. 2018 Aug; 5(9): 1077-88.
27. Huntsman RJ, Tang-Wai R, Alcorn J, et al. Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E Study. Front Neurol. 2019 Jul; 10: 716.
28. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016 Feb;35:41-4.
29. Caraballo R, Valenzuela GR. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: a study of eight patients. Seizure. 2021 Nov;92: 238-43.